Speaker(s): 

Dennis Marjoncu, PharmD, BCOP, Staff Member, Duquesne University School of Pharmacy - has nothing to disclose.

Moderator(s): 

Daniel Longyhore, PharmD, EdD, BCACP, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe BiTE therapy mechanisms and how they relate to cytokine release syndrome (CRS) and immune effector-cell associated neurotoxicity syndrome (ICANS)
• Differentiate between the different severity grades of CRS and ICANS
• Apply knowledge about CRS and ICANS to patient cases.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, EdD, BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH and Lisabeth Karetsky, CPhT have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None